NEW YORK, September 28, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Amedica Corporation (NASDAQ: AMDA), Accuray
Incorporated (NASDAQ: ARAY), Acadia Healthcare Company,
Inc. (NASDAQ: ACHC), ANI Pharmaceuticals, Inc. (NASDAQ:
ANIP), Akebia Therapeutics, Inc. (NASDAQ: AKBA). On
Friday, September 25, 2015, Nasdaq
ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish
the day at 16,314.67, and the S&P closed at 1,931.34, down
0.05%. Register for your complimentary reports at the links given
below.
--
Amedica Corp
--
Amedica Corp's stock edged lower by 3.44% to close Friday's
session at USD 0.35. The company's
shares oscillated between USD 0.35 and USD
0.38 in trade during the day. The stock recorded a trading
volume of 1.16 million shares, which was below its 50-day daily
average volume of 2.00 million shares and below its 52-week average
volume of 1.77 million shares. Over the last three days, Amedica
Corp's shares have declined by 11.76% and in the past one week it
has moved down 19.13%. Furthermore, over the last three months, the
stock has lost 40.52% and in the past six months, the shares have
shed 17.84%. Sign up and read the free notes on AMDA at:
http://www.aciassociation.com/AMDA.pdf
--
Accuray Inc.
--
The stock of Accuray Inc. lost 5.71% to close Friday's session
at USD 5.61. The shares of the
company moved in the range of USD
5.56 and USD 6.02 marking a
new 52-week low during the session. A trading volume of 1.15
million shares was recorded, which was lower than its 150-day daily
average volume of 1.27 million shares and above its 52-week average
volume of 1.13 million shares. Over the last five days, Accuray
Inc.'s shares have declined by 10.67% and in the past one month, it
has lost 13.29%. Additionally, over the last three months, the
stock has declined 17.86% and in the past six months, the shares
have registered a loss of 39.68%. The stock is trading at a price
to book ratio of 5.88, which compares to a historical PB ratio
close to 7.07. Further, the stock is trading at a price to cash
flow ratio of 86.12 and price to sales ratio of 1.18. Register for
free on ACI Association and access the latest research on ARAY at:
http://www.aciassociation.com/ARAY.pdf
--
Acadia Healthcare Company Inc.
--
Acadia Healthcare Company Inc.'s stock decreased by 3.93% to
close Friday's session at USD 70.38.
The company's shares fluctuated in the range of USD 69.69 and USD
74.33. A total of 1.01 million shares exchanged hands, which
surpassed its 50-day daily average volume of 0.68 million shares
and was above its 52-week average volume of 0.54 million shares.
Over the last three days Acadia Healthcare Company Inc.'s shares
have declined by 5.16% and in the past one week it has moved down
6.98%. Furthermore, over the last three months, the stock has lost
7.21% and in the past six months, the shares have shed 2.24%.
Further, the stock is trading at a price to earnings ratio of
46.30. This compares to a historical PE ratio of 40.69. The
complete research on ACHC is available for free at:
http://www.aciassociation.com/ACHC.pdf
--
ANI Pharmaceuticals Inc.
--
ANI Pharmaceuticals Inc.'s stock slipped by 6.47% to close
Friday's session at USD 43.21. The
company's shares oscillated between USD
41.53 and USD 47.55 in trade during the day. The stock
recorded a trading volume of 1.00 million shares, which was above
its 50-day daily average volume of 0.35 million shares and above
its 52-week average volume of 0.31 million shares. Over the last
five days, ANI Pharmaceuticals Inc.'s shares have declined by
18.58% and in the past one month, it has lost 9.92%. In addition,
over the last three months, the stock has lost 31.16% and year to
date, the shares have shed 23.37%. Further, the company is trading
at a price to earnings ratio of 13.94. This compares to a
historical PE ratio of 21.80. Free in-depth research on ANIP is
available at: http://www.aciassociation.com/ANIP.pdf
--
Akebia Therapeutics Inc.
--
Akebia Therapeutics Inc.'s stock declined 5.11% to close
Friday's session at USD 10.58. The
share price vacillated between USD 10.42 and
USD 11.55. The stock recorded a trading volume of 0.89
million shares, which was below its 50-day daily average volume of
0.93 million shares and above its 52-week average volume of 0.41
million shares. Over the last three days Akebia Therapeutics Inc.'s
shares have declined by 5.11% and in the past one week it has moved
down 6.62%. Moreover, in the last six months, the stock has gained
1.44% and year to date, the shares have shed 9.11. The
complimentary notes on AKBA can be downloaded in PDF format at:
http://www.aciassociation.com/AKBA.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been
sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com